Contra-indicated in organ transplant recipients. Orlistat interferes with the medicines used to prevent transplant rejection.
- TRADE NAMES: Alli (GSK); Xenical (Roche)
- INDICATIONS:
Obesity, weight reduction.
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions.
- CLASS: Anti-obesity / weight loss pharmacotherapy, Lipase inhibitor
- HALF-LIFE: 1–2 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acarbose, Amiodarone, Antiepileptics, Coumarins, Cyclosporine, Ergocalciferol, Ethosuximide, Lacosamide, Levothyroxine, Oxcarbazepine, Paricalcitol, Phytonadione, Tiagabine, Vigabatrin, Vitamin A, Vitamin E, Warfarin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of orlistat in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/28/2025
